Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jimmy Extension rollover study of GME751 in participants continuing pembrolizumab treatment after prior GME751 studies
jRCT2031240454Active, not recruiting
- Sponsor
- Hexal AG
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of GME751 in non-small cell lung cancer (NSCLC), sponsored by Hexal AG. Primary endpoint: Occurrence of serious adverse events. Started Aug 2025; status: active, not recruiting.
02
Drugs
GME751
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240454.